We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Cabotegravir Is Not Associated With Weight Gain in Human Immunodeficiency Virus–uninfected Individuals in HPTN 077.
- Authors
Landovitz, Raphael J; Zangeneh, Sahar Z; Chau, Gordon; Grinsztejn, Beatriz; Eron, Joseph J; Dawood, Halima; Magnus, Manya; Liu, Albert Y; Panchia, Ravindre; Hosseinipour, Mina C; Kofron, Ryan; Margolis, David A; Rinehart, Alex; Adeyeye, Adeola; Burns, David; McCauley, Marybeth; Cohen, Myron S; Currier, Judith S
- Abstract
Studies in human immunodeficiency virus (HIV)–infected individuals suggest excess weight gain with integrase inhibitor–based antiretroviral therapy. The HIV Prevention Trials Network Study 077 evaluated changes in weight and fasting metabolic parameters in HIV-uninfected individuals randomized to cabotegravir or a placebo. No differences between arms were found for change in weight or fasting metabolic parameters overall or for subgroups.
- Subjects
HIV prevention; BASAL metabolism; FASTING; STATISTICAL sampling; WEIGHT gain; RANDOMIZED controlled trials; TREATMENT effectiveness; HIV integrase inhibitors; PHARMACODYNAMICS
- Publication
Clinical Infectious Diseases, 2020, Vol 70, Issue 2, p319
- ISSN
1058-4838
- Publication type
Article
- DOI
10.1093/cid/ciz439